LV10262B - Process for producing pharmaceutical compounds - Google Patents

Process for producing pharmaceutical compounds

Info

Publication number
LV10262B
LV10262B LVP-93-517A LV930517A LV10262B LV 10262 B LV10262 B LV 10262B LV 930517 A LV930517 A LV 930517A LV 10262 B LV10262 B LV 10262B
Authority
LV
Latvia
Prior art keywords
pharmaceutical compounds
producing pharmaceutical
methyl
producing
thieno
Prior art date
Application number
LVP-93-517A
Other languages
English (en)
Other versions
LV10262A (lv
Inventor
Jiban Kumar Chakrabarti
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10262(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of LV10262A publication Critical patent/LV10262A/xx
Publication of LV10262B publication Critical patent/LV10262B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
LVP-93-517A 1990-04-25 1993-06-08 Process for producing pharmaceutical compounds LV10262B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
LV10262A LV10262A (lv) 1994-10-20
LV10262B true LV10262B (en) 1995-04-20

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-517A LV10262B (en) 1990-04-25 1993-06-08 Process for producing pharmaceutical compounds

Country Status (33)

Country Link
EP (1) EP0454436B1 (fr)
JP (1) JP2527860B2 (fr)
KR (1) KR100195566B1 (fr)
CN (1) CN1028429C (fr)
AT (1) ATE127804T1 (fr)
AU (1) AU643267B2 (fr)
BG (1) BG61710B2 (fr)
CA (1) CA2041113C (fr)
CY (1) CY1900A (fr)
CZ (1) CZ279937B6 (fr)
DE (3) DE69112895T4 (fr)
DK (1) DK0454436T3 (fr)
ES (1) ES2078440T3 (fr)
FI (1) FI101379B1 (fr)
GB (1) GB9009229D0 (fr)
GE (1) GEP20032965B (fr)
GR (1) GR3017877T3 (fr)
HK (1) HK87596A (fr)
HU (2) HU212416B (fr)
IE (1) IE68401B1 (fr)
IL (2) IL97912A (fr)
LU (2) LU90009I2 (fr)
LV (1) LV10262B (fr)
MX (1) MX173791B (fr)
NL (2) NL970015I2 (fr)
NO (3) NO178766C (fr)
NZ (1) NZ237932A (fr)
PT (1) PT97446B (fr)
RU (1) RU2043992C1 (fr)
SI (1) SI9110739A (fr)
SK (1) SK279196B6 (fr)
YU (1) YU48049B (fr)
ZA (1) ZA913085B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
DK0582368T3 (da) * 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
ES2180643T3 (es) * 1995-05-30 2003-02-16 Lilly Co Eli Procedimiento para tratar la disfuncion cognitiva.
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
JP2000502346A (ja) * 1995-12-21 2000-02-29 イーライ・リリー・アンド・カンパニー 皮膚炎の処置方法
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CZ299247B6 (cs) * 1996-09-23 2008-05-28 Eli Lilly And Company Olanzapin dihydrát D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
DE69816102D1 (de) 1997-09-02 2003-08-07 Mitsubishi Pharma Corp Kondensierte thiophenderivate und ihre medizinische anwendung
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
KR100537713B1 (ko) * 1997-09-30 2005-12-20 일라이 릴리 앤드 캄파니 2-메틸-티에노-벤조디아제핀 제제
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
SK2502003A3 (en) 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CA2471341C (fr) * 2001-12-24 2012-01-24 Sun Pharmaceutical Industries Limited Forme cristalline de 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
US20040063694A1 (en) * 2002-06-05 2004-04-01 Browder Monte R. Compound useful for the treatment of CNS disorders
PL199016B1 (pl) 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) * 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
DE602004014264D1 (de) 2003-12-22 2008-07-17 Teva Pharma Verfahren zur herstellung von olanzapin
AR047461A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Formacion, purificacion y uso de n-formilolanzapina
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (fr) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Procedes ameliores pour la synthese de l'olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (fr) 2011-02-14 2012-08-15 Labtec GmbH Formulation de film oral à désintégration rapide pour olanzapine
WO2012153347A2 (fr) 2011-05-04 2012-11-15 Zentiva K.S. Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (fr) * 2011-10-31 2013-05-10 Mahmut Bilgic Formulations antipsychotiques hydrosolubles
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
US20150216206A1 (en) 2012-07-31 2015-08-06 Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi Method for increasing meat and milk production
EP2879518A1 (fr) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. Utilisation d'olanzapine chez des animaux
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法
WO2025056094A1 (fr) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 Préparation lyophilisée, injection, et procédé de préparation associé

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
HU911372D0 (en) 1991-10-28
HU211575A9 (en) 1995-12-28
MX173791B (es) 1994-03-25
NO178766C (no) 1996-05-29
NO178766B (no) 1996-02-19
LV10262A (lv) 1994-10-20
GR3017877T3 (en) 1996-01-31
ATE127804T1 (de) 1995-09-15
IE911348A1 (en) 1991-11-06
CS9101168A2 (en) 1991-12-17
NO911624D0 (no) 1991-04-24
DE19675046I2 (de) 2001-05-23
KR910018387A (ko) 1991-11-30
GEP20032965B (en) 2003-05-12
NL970015I1 (nl) 1997-06-02
IL112575A0 (en) 1995-05-26
MX25502A (es) 1993-10-01
CN1028429C (zh) 1995-05-17
CA2041113A1 (fr) 1991-10-26
HK87596A (en) 1996-05-24
JP2527860B2 (ja) 1996-08-28
NO911624L (no) 1991-10-28
IL97912A (en) 1995-10-31
HUT60503A (en) 1992-09-28
KR100195566B1 (ko) 1999-06-15
AU643267B2 (en) 1993-11-11
FI101379B (fi) 1998-06-15
LU90869I2 (fr) 2002-02-21
JPH0789965A (ja) 1995-04-04
FI911986A0 (fi) 1991-04-24
IE68401B1 (en) 1996-06-12
SI9110739A (en) 1997-10-31
HU212416B (en) 1996-06-28
NO1997005I1 (no) 1997-05-12
NZ237932A (en) 1993-08-26
NL300078I1 (nl) 2002-03-01
SK279196B6 (sk) 1998-07-08
PT97446B (pt) 1997-07-31
DK0454436T3 (da) 1995-11-13
DE69112895T4 (de) 2009-11-12
CA2041113C (fr) 1998-07-14
GB9009229D0 (en) 1990-06-20
RU2043992C1 (ru) 1995-09-20
YU48049B (sh) 1996-10-18
CN1056693A (zh) 1991-12-04
ZA913085B (en) 1992-12-30
FI101379B1 (fi) 1998-06-15
AU7518691A (en) 1991-11-07
DE69112895D1 (de) 1995-10-19
BG61710B2 (bg) 1998-03-31
ES2078440T3 (es) 1995-12-16
EP0454436A1 (fr) 1991-10-30
NL970015I2 (nl) 1997-09-01
EP0454436B1 (fr) 1995-09-13
LU90009I2 (fr) 1997-01-31
CZ279937B6 (cs) 1995-09-13
NO2001028I1 (no) 2002-01-28
FI911986L (fi) 1991-10-26
PT97446A (pt) 1992-01-31
YU73991A (sh) 1994-01-20
CY1900A (en) 1991-04-24
DE69112895T2 (de) 1996-03-07
IL97912A0 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
LV10262B (en) Process for producing pharmaceutical compounds
TW372872B (en) Thieno[1,5]benzodiazepine use
HUT52769A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions containing them
AU6760987A (en) Method of treating alzheimer's disease
ZA904991B (en) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'-e)(1,4)-diazepin-6-ones and-thiones and their use for the treatment of aids
AU4856893A (en) 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo{2,3-b}heterocyclic -2-one useful in the treatment of cognitive disorders of man
ES2058029A1 (es) Proceso para la produccion de sales del acido clavulanico.
EP0383171A3 (fr) Dérivés de 2,3,23 trihydroxy-urs-12-ène pour le traitement des troubles cognitifs
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
TW221439B (fr)
EP0516914A3 (en) Highly pure phosphatidylinositol of natural source useful for the treatment of central nervous system disorders and process for its preparation
HU9200400D0 (en) Cinurenic acid derivatives, process for producing them and pharmaceutical compositions containing them
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned